Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

2013119 citationsJournal Article

Authors

Norihiro Nishimoto · Tokyo Medical University

Koichi Amano · Saitama Medical University

Yasuhiko Hirabayashi

Takahiko Horiuchi · Kyushu University

Tomonori Ishii · Tohoku University

Mitsuhiro Iwahashi · Higashihiroshima Medical Center

Masahiro Iwamoto · Jichi Medical University

Abstract

TCZ monotherapy may induce biologics-free remission or LDA without concomitant use of synthetic DMARDs. Serum levels of IL-6 and MMP-3 are useful markers for identifying patients who could discontinue TCZ without acute disease flare.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Toxin Mechanisms and Immunotoxins Autoimmune and Inflammatory Disorders Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Modern Rheumatology

Volume 24, Issue 1, pp. 17-25

DOI: 10.3109/14397595.2013.854079

Field-Weighted Citation Impact: 9.62